Mosunetuzumab (Genetical Recombination)



Mosunetuzumab is a recombinant bispecific monoclonal antibody against CD20 and CD3ε chain, which is composed of anti-CD20 antibody and anti-CD3ε chain antibody whose complementarity-determining regions are derived from respective mouse antibodies and other regions are derived from human IgG1. In the anti-CD20-H-chain, the amino acid residues are substituted at 2 positions (N302G, T371W). In the anti-CD3ε-H-chain, the amino acid residues are substituted at 4 positions (N299G, T368S, L370A, Y409V). Mosunetuzumab is produced in CHO cells. Mosunetuzumab is a protein composed of an anti-CD20-H-chain (γ1-chain) consisting of 452 amino acid residues, an anti-CD20-L-chain (κ-chain) consisting of 213 amino acid residues, an anti-CD3ε-H-chain (γ1-chain) consisting of 449 amino acid residues, and an anti-CD3ε-L-chain (κ-chain) consisting of 219 amino acid residues.

[1905409-39-3]